Reuters logo
BRIEF-Prima Biomed says approval has been granted for third cohort of its phase i clinical trial for IMP321 in combination with KEYTRUDA
April 19, 2017 / 1:44 AM / 7 months ago

BRIEF-Prima Biomed says approval has been granted for third cohort of its phase i clinical trial for IMP321 in combination with KEYTRUDA

April 19 (Reuters) - Prima Biomed Ltd-

* Asx alert-approval received to commence 3rd cohort of melanoma trial-prr.ax

* Approval has been granted for third cohort of its phase i clinical trial for imp321 in combination with keytruda Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below